VAL201

VAL201 is a synthetic short decapeptide developed as an antineoplastic agent for the treatment of prostate cancer and other solid tumors. Its mechanism of action involves inhibition of Src-family kinases and antagonism of the androgen receptor pathway. By targeting these pathways, VAL201 aims to reduce tumor proliferation and metastasis in hormone-resistant cancers. The drug was originally inspired by naturally occurring androgen receptor regulatory peptides. Developed by ValiRx (with originator Cancer Research Technology), it has undergone Phase 1/2 clinical trials in patients with locally advanced or metastatic prostate cancer, demonstrating safety and tolerability as well as evidence for disease impact such as increased PSA doubling time and stabilization of metastatic lesions[2][3][5]. Development for endometriosis and inflammation has been discontinued[2].

Other names

VAL 201VAL201VAL-201VAL-301VAL301VAL 301